Jefferies Group’s Checkpoint Therapeutics CKPT Stock Holding History

Jefferies Group’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,260	Closed	-$36K	–	2562
2019 Q1	$36K	Buy	+1,260	New	+$40.2K	﹤0.01%	2220

Other funds holding CKPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jefferies Group's CKPT Position: Q2 2019 in Review

Jefferies Group sold out of Checkpoint Therapeutics (CKPT) in Q2 2019, closing a stake of 1,260 shares — an estimated $36K sold.

Jefferies Group first reported a position in CKPT in Q1 2019 and held it in 1 quarter. The position peaked at $36K in Q1 2019. 40 funds tracked by Wall St. Rank hold CKPT as of Q2 2019.

Jefferies Group reported no remaining Checkpoint Therapeutics position as of Q2 2019 after selling out during the quarter.
Jefferies Group sold 1,260 Checkpoint Therapeutics shares in Q2 2019, an estimated $36K.
Jefferies Group first reported a position in Checkpoint Therapeutics in Q1 2019 and held it in 1 quarter.
Jefferies Group's Checkpoint Therapeutics position peaked at $36K in Q1 2019.
40 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2019.

Based on Jefferies Group's 13F filing for Q2 2019, filed 14 Aug 2019.